142 related articles for article (PubMed ID: 1582698)
1. Inhibition of neutrophil respiratory burst and degranulation responses to platelet-activating factor by antagonists WEB 2086, CV 6209 and CV 3988.
Bates EJ; Harvey DP; Ferrante A
Int Arch Allergy Immunol; 1992; 97(1):50-6. PubMed ID: 1582698
[TBL] [Abstract][Full Text] [Related]
2. Platelet-activating factor inhibits proteoglycan synthesis and enhances neutrophil-mediated proteoglycan degradation in cartilage explants.
Kowanko IC; Bates EJ; Ferrante A
Arthritis Rheum; 1992 Aug; 35(8):918-25. PubMed ID: 1322671
[TBL] [Abstract][Full Text] [Related]
3. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
Koike H; Imanishi N; Natsume Y; Morooka S
Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
[TBL] [Abstract][Full Text] [Related]
4. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study).
Munoz-Cano R; Ainsua-Enrich E; Torres-Atencio I; Martin M; Sánchez-Lopez J; Bartra J; Picado C; Mullol J; Valero A
J Investig Allergol Clin Immunol; 2017; 27(3):161-168. PubMed ID: 27758758
[TBL] [Abstract][Full Text] [Related]
5. Pro-inflammatory response of alveolar macrophages induced by sulphite: studies with lucigenin-dependent chemiluminescence.
Beck-Speier I; Dayal N; Maier KL
J Biolumin Chemilumin; 1998; 13(2):91-9. PubMed ID: 9633012
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of neutrophil adherence to vascular endothelial cells by histamine and thrombin and its inhibition by PAF antagonists and dexamethasone.
Watanabe M; Yagi M; Omata M; Hirasawa N; Mue S; Tsurufuji S; Ohuchi K
Br J Pharmacol; 1991 Jan; 102(1):239-45. PubMed ID: 2043925
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of reversible priming of human neutrophils using platelet-activating factor.
Kitchen E; Rossi AG; Condliffe AM; Haslett C; Chilvers ER
Blood; 1996 Dec; 88(11):4330-7. PubMed ID: 8943870
[TBL] [Abstract][Full Text] [Related]
9. Platelet-activating factor induces a concentration-dependent spectrum of functional responses in bovine neutrophils.
Swain SD; Bunger PL; Sipes KM; Nelson LK; Jutila KL; Boylan SM; Quinn MT
J Leukoc Biol; 1998 Dec; 64(6):817-27. PubMed ID: 9850166
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of human neutrophil defense activities through activation of platelet-activating factor receptors by ginkgolide B, a bioactive component of the Ginkgo biloba extract EGB 761.
Lenoir M; Pedruzzi E; Rais S; Drieu K; Perianin A
Biochem Pharmacol; 2002 Apr; 63(7):1241-9. PubMed ID: 11960600
[TBL] [Abstract][Full Text] [Related]
11. Mouse and human eosinophils degranulate in response to platelet-activating factor (PAF) and lysoPAF via a PAF-receptor-independent mechanism: evidence for a novel receptor.
Dyer KD; Percopo CM; Xie Z; Yang Z; Kim JD; Davoine F; Lacy P; Druey KM; Moqbel R; Rosenberg HF
J Immunol; 2010 Jun; 184(11):6327-34. PubMed ID: 20421642
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological analysis of neutrophil chemotactic factor production by leucocytes and roles of PAF in allergic inflammation in rats.
Watanabe M; Arakida Y; Tanabe J; Sugidachi A; Hirasawa N; Mue S; Ohuchi K
Br J Pharmacol; 1994 Jan; 111(1):123-30. PubMed ID: 8012688
[TBL] [Abstract][Full Text] [Related]
13. [Characterization of platelet-activating factor (PAF)-receptors in neutrophilic and eosinophilic granulocytes].
Ukena D; Dent G; Chanez P; Barnes PJ; Sybrecht GW
Pneumologie; 1990 Feb; 44 Suppl 1():531-2. PubMed ID: 2164200
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of neutrophil and eosinophil chemotactic responses to PAF by the PAF-antagonists WEB-2086, L-652,731, and SRI-63441.
Håkansson L; Venge P
J Leukoc Biol; 1990 May; 47(5):449-56. PubMed ID: 2335754
[TBL] [Abstract][Full Text] [Related]
15. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis.
Biancone L; Cantaluppi V; Boccellino M; Bussolati B; Del Sorbo L; Conaldi PG; Albini A; Toniolo A; Camussi G
Am J Pathol; 1999 Nov; 155(5):1731-9. PubMed ID: 10550329
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary vascular reactivity: effect of PAF and PAF antagonists.
Chen CR; Voelkel NF; Chang SW
J Appl Physiol (1985); 1992 Nov; 73(5):1762-9. PubMed ID: 1474049
[TBL] [Abstract][Full Text] [Related]
17. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
[TBL] [Abstract][Full Text] [Related]
18. Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells.
Workman P; Donaldson J; Lohmeyer M
Biochem Pharmacol; 1991 Jan; 41(2):319-22. PubMed ID: 1989642
[No Abstract] [Full Text] [Related]
19. A comparison of the actions of platelet activating factor (PAF) antagonists WEB 2170 and WEB 2086 in the horse.
Foster AP; Cunningham FM; Andrews MJ; Lees P
J Vet Pharmacol Ther; 1993 Dec; 16(4):477-87. PubMed ID: 8126765
[TBL] [Abstract][Full Text] [Related]
20. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor.
Smiley PL; Stremler KE; Prescott SM; Zimmerman GA; McIntyre TM
J Biol Chem; 1991 Jun; 266(17):11104-10. PubMed ID: 1645725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
